The Brightline-2 trial is funded by Boehringer Ingelheim. The authors did not receive payment related to the development of this manuscript. C Yoo has received honoraria from Servier, Bayer, AstraZeneca, Merck Sharp & Dohme, Eisai, Celgene, Bristol Myers Squibb, Ipsen, Novartis, Boryung Pharmaceuticals, Mundipharma, Boehringer Ingelheim, and Roche; and received research grants from Servier, Bayer, AstraZeneca, Ono Pharmaceuticals, Ipsen, and Boryung Pharmaceuticals. A Lamarca has consulting/advisory roles with Nutricia, Ipsen, QED Therapeutics, Roche, Servier, Boston Scientific, Albireo Pharma, and AstraZeneca/MedImmune; serves on the speakers' bureau for Merk, Ipsen, Pfizer, Novartis, Incyte, Advanced Accelerator Applications, QED Therapeutics, Servier, and AstraZeneca/MedImmune; has received travel, accommodations, and/or expenses from Abbott Nutrition, Ipsen, Pfizer, Celgene, Novartis, Advanced Accelerator Applications, Sirtex Medical, Bayer, Delcath Systems, and Mylan; and has received research funding from Ipsen and Roche. HY Choi has no interests to disclose. A Vogel has advisory council/committee roles with AstraZeneca, Amgen, BeiGene, and Böhringer Mannheim; and has received honoraria from AstraZeneca, Amgen, BeiGene, Böhringer Mannheim, Bristol Myers Squibb, BTG, Daichi-Sankyo, Eisai, GSK, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Jiangsu Hengrui Medicines MSD, PierreFabre, Roche, Servier, Sirtex, Tahio, and Terumo. MJ Pishvaian has advisory roles with Astra Zeneca, Ideaya, Seattle Genetics, Merus, and Merck; has received honoraria from Pfizer and Novartis; is on the steering committee for Astellas and Trisalus; has received travel expenses from Astellas and RenovoRx; has stocks and patent at Perthera; has patent pending with Abbvie; has continuing medical education activities with Tumor Board Tuesdays and TRICC; and reports funding to the institution from Seattle Genetics, Tesaro, Arcus Bio, Ideaya, Repare Tx, Novartis, Pfizer, Merck, Tizonia, Biomed Valley Discoveries, Amgen, RenovoRx, Boehringer Ingelheim, Astellas, Hutchinson, Medipharma, Takeda, Actuate, and MEI Pharma. L Goyal has a consulting role with Abbvie. M Ueno reports grants to the institution from Taiho Pharmaceutical, AstraZeneca, Merck Biopharma, MSD, Astellas Pharma, Eisai, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, DFP Pharma, Daiichi Sankyo, Novartis, Boehringer Ingelheim, and J-pharma; and has received honoraria from Taiho Pharmaceutical, AstraZeneca, Yakult Honsha, MSD, Nihon, Servier, Ono Pharmaceutical, Incyte, Chugai Pharmaceutical, Boehringer Ingelheim, and J-Pharma. A Märten, M Teufel, and L Geng are employed by Boehringer Ingelheim. C Morizane has received honoraria from Novartis, Yakult Honsha, Teijin Pharma, Taiho, Pharmaceutical, Eisai, MSD K.K., and AstraZeneca; has grants/funds from Boehringer Ingelheim, Eisai, Yakult Honsha, ONO Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck biopharma, Daiichi Sankyo RD, Novare, and Hitachi; and has advisory roles with Boehringer Ingelheim, Merck, Taiho Pharmaceutical, AstraZeneca, Servier, MSD K.K., and Yakult Honsha. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.